Ipragliflozin

CHEMBL2018096 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

404.5 g/mol

LogP

2.5

Phase

4

This SGLT2 inhibitor works by blocking a kidney protein that reabsorbs glucose, causing excess sugar to be excreted in the urine and thereby lowering blood sugar levels in people with type 2 diabetes. It also promotes modest weight loss and blood pressure reduction.

Berat Molekul

404,5000 g/mol

LogP

2,50

TPSA

118,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Non-Alcoholic Fatty Liver Disease Type 2 Diabetes

Mekanisme Kerja

Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O

InChI

InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1

Molecular Formula

C21H21FO5S

HBD / HBA

4 / 7

Ikatan yang Dapat Dirotasi

4

Atom Berat

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This SGLT2 inhibitor works by blocking a kidney protein that reabsorbs glucose, causing excess sugar to be excreted in the urine and thereby lowering blood sugar levels in people with type 2 diabetes. It also promotes modest weight loss and blood pressure reduction.

Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.

Yes, Ipragliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2018096. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 10453870. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Ipragliflozin di PillFYI

Struktur

Data Cepat

Rumus: C21H21FO5S

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Ipragliflozin

Area Terapeutik

Mekanisme Kerja

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Pertanyaan yang Sering Diajukan

References & Data Sources

Embed This Widget